免疫相关不良事件或可预测BRAF V600突变转移性黑色素瘤患者对BRAF抑制剂的持久缓解
该回顾性队列纳入78例BRAF V600突变转移性黑色素瘤患者,接受BRAFi或BRAFi+MEKi治疗,定义白癜风、葡萄膜炎、结节性红斑和干燥性角膜炎为感兴趣的irAEs。发生至少一种irAE的患者中位PFS为42.8个月,未发生者为6.1个月(HR 0.22,p=0.002),且独立于LDH水平和疾病负荷。
要点
- 发生irAE者中位PFS 42.8个月,未发生者6.1个月(HR 0.22,p=0.002)。
- 该关联独立于LDH水平和疾病负荷(HR 0.24,p=0.035)。
- irAE或可作为靶向治疗持久缓解的治疗相关生物标志物。
核心结论
- 免疫相关不良事件与BRAF抑制剂靶向治疗的持久缓解强相关,或可作为评估治疗结局的治疗相关生物标志物。
主要发现
- 全部患者中位PFS为7.5个月,截至2017年4月有8例患者缓解持续。
- 10例患者发生预先定义的irAEs(白癜风、葡萄膜炎、结节性红斑、干燥性角膜炎)。
- 发生至少一种irAE者中位PFS为42.8个月,未发生者为6.1个月(HR 0.22,p=0.002)。
- 校正LDH水平和疾病负荷后关联仍显著(HR 0.24,p=0.035)。
临床怎么用
- 在接受BRAFi或BRAFi+MEKi治疗的BRAF V600突变转移性黑色素瘤患者中,关注白癜风、葡萄膜炎、结节性红斑和干燥性角膜炎等irAEs,或有助于预估持久缓解。
局限性
- 回顾性研究设计,样本量78例,irAE事件数较少(10例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are among the cornerstones of metastatic melanoma therapy demonstrating excellent response rates with duration of 7-12 m. Long-term benefit from these agents was reported in patients with normal lactate dehydrogenase (LDH) and less than three disease sites. However, a treatment-dependent marker for long-term efficacy is lacking. Data suggest that immune-related adverse events (irAEs) are associated with clinical benefit in patients treated with immunotherapy and that response to BRAF/MEK therapy may have an underlying immune mechanism. We hypothesised that AEs with an underlying immune mechanism may be associated with a durable response to targeted therapy. We retrospectively identified a cohort of 78 BRAF V600-mutant metastatic melanoma patients treated with BRAFi or BRAFi + MEKi between November 2010 and November 2013. Four treatment-related AEs including vitiligo, uveitis, erythema nodosum and keratitis sicca were defined as irAEs of interest. Retrospective analysis of AEs in relationship to progression-free survival (PFS), disease burden and LDH levels was performed. Median PFS (mPFS) for all patients was 7.5 months with responses ongoing in eight patients as of April 2017. Ten patients were identified with the AEs defined previously. Cox regression analysis revealed a very strong association between those AEs and PFS; mPFS was 42.8 m in patients with at least one AE versus 6.1 m in those without an AE (hazard ratio [HR] 0.22, p = 0.002). This association was independent of LDH levels and disease burden (HR 0.24, p = 0.035). This analysis demonstrates a strong association between immune AEs and durable response to targeted therapy and may provide a treatment-related biomarker to estimate the outcome of therapy.
引用
- Ben-Betzalel G, Baruch EN, Boursi B, et al. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer. 2018. PMID: 30096703. doi:10.1016/j.ejca.2018.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。